Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Luft

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
Blood|January 10, 2024
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signatureAnna Mathioudaki, Xizhe Wang, David Sedloev, et al.
Blood Vessels, Thrombosis & Hemostasis|December 3, 2025
Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkersLaura Simons, Lina Alasfar, Muath Qadoura, et al.
Vaccines|February 26, 2022
Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell TransplantationCaroline Pabst, Louise Benning, Nora Liebers, et al.
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
British Journal of Haematology|September 13, 2021
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMTAvichai Shimoni, Marie Robin, Simona Iacobelli, et al.
Blood Advances|December 22, 2020
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparisonPeter Dreger, Sascha Dietrich, Maria-Luisa Schubert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumorsEugene Maraskovsky, Sigrid Sjölander, Debbie P Drane, et al.
Bone Marrow Transplantation|August 19, 2025
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working partyDrazen Pulanic, Christophe Peczynski, William Boreland, et al.
Cytotherapy|October 29, 2021
Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cellsMing Ni, Lei Wang, Yuntian Ding, et al.
Blood Advances|September 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AMLJulia M Unglaub, Richard F Schlenk, Jan Moritz Middeke, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Blood|January 10, 2024
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signatureAnna Mathioudaki, Xizhe Wang, David Sedloev, et al.
Blood Vessels, Thrombosis & Hemostasis|December 3, 2025
Comprehensive assessment of endothelial dysfunction before cellular therapy: EASIX, local imaging, and systemic biomarkersLaura Simons, Lina Alasfar, Muath Qadoura, et al.
Vaccines|February 26, 2022
Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell TransplantationCaroline Pabst, Louise Benning, Nora Liebers, et al.
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
British Journal of Haematology|September 13, 2021
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMTAvichai Shimoni, Marie Robin, Simona Iacobelli, et al.
Blood Advances|December 22, 2020
CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparisonPeter Dreger, Sascha Dietrich, Maria-Luisa Schubert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumorsEugene Maraskovsky, Sigrid Sjölander, Debbie P Drane, et al.
Bone Marrow Transplantation|August 19, 2025
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working partyDrazen Pulanic, Christophe Peczynski, William Boreland, et al.
Cytotherapy|October 29, 2021
Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cellsMing Ni, Lei Wang, Yuntian Ding, et al.
Blood Advances|September 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AMLJulia M Unglaub, Richard F Schlenk, Jan Moritz Middeke, et al.
Pageof 12